Orphan drugs

Statistics report about the orphan drugs industry and market

Orphan drugs

This report presents key facts and figures about the global and U.S. orphan drugs market. Orphan drugs are medications which are used for so called rare diseases, a group of conditions which affects a very small group of a population. This report provides a closer look on top companies, top products, research and development, treatment costs, etc.

Table of contents

Rare diseases

4
  • Basic Statistic Prevalence of selected rare diseases worldwide 2017
  • Basic Statistic Overview of rare diseases worldwide and in the U.S. as of 2016
  • Premium Statistic Impact of medicines on life expectancy for select rare diseases worldwide as of 2017
  • Basic Statistic Distribution of U.S. patients with rare factor deficiencies as of 2024, by gender

Market overview

5
  • Basic Statistic Projection of global revenue for orphan prescription drugs 2016-2028
  • Premium Statistic Price comparison of most expensive drugs U.S. 2024
  • Basic Statistic Worldwide share of orphan drug sales by therapy category 2023 vs. 2028
  • Basic Statistic Global rare disease diagnostics market size 2019 and 2030
  • Basic Statistic Global rare disease diagnostics market size 2019 and 2030 by therapy area

Companies

4
  • Premium Statistic Top 50 pharmaceutical companies - Rx sales and R&D spending 2023
  • Premium Statistic Top global companies by orphan drug revenues 2023
  • Premium Statistic Top 10 companies by global revenue from orphan drugs 2028
  • Basic Statistic Orphan drugs sales share among top pharma companies 2028 forecast

Products

6
  • Premium Statistic Projection of top orphan drugs by global revenue 2028
  • Premium Statistic Number of orphan designations accepted in the U.S. 2003-2023
  • Basic Statistic Oncology or orphan drug share in approved new active substances 2015-2022
  • Premium Statistic FDA approved orphan drugs with non-orphan indications 1983-2018
  • Basic Statistic Share of new orphan drugs available in Europe in 2024, by country
  • Basic Statistic Time between orphan drugs approval and patient access in Europe 2024, by country

Research and development

6
  • Premium Statistic Total global pharmaceutical R&D spending 2014-2030
  • Premium Statistic Total rare diseases funding by the National Institutes for Health 2013-2025
  • Basic Statistic Orphan and non-orphan drugs in the pipeline worldwide 2021
  • Basic Statistic Leading orphan drugs in development based on net present value 2024
  • Basic Statistic Orphan vs. non-orphan pipeline sales forecast worldwide 2023-2028
  • Premium Statistic U.S. development Phase success rates for rare and common disease drugs 2011-2020

Statista report shop

Explore all Statista reports

We provide information on industries, companies, consumers, trends, countries, and politics, covering the latest and most important issues in a condensed format.

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)